Progression-free, overall survival prolonged with lenvatinib plus pembrolizumab versus treating physician’s choice of chemotherapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 31, 2022 (HealthDay News) — For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy, according to a study published online Jan. 19 in the New England Journal of Medicine<\/em>.<\/p>\n Vicky Makker, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues randomly assigned 827 patients with advanced endometrial cancer (697 with mismatch repair-proficient [pMMR] disease and 130 with mismatch repair-deficient disease) that had progressed or recurred after at least one platinum-based chemotherapy regimen to receive either lenvatinib plus pembrolizumab or chemotherapy of the treating physician’s choice (411 and 416 patients, respectively).<\/p>\n The researchers found that longer median progression-free survival occurred with lenvatinib plus pembrolizumab than with chemotherapy (overall: 7.2 versus 3.8 months; hazard ratio, 0.56; pMMR population: 6.6 versus 3.8 months; hazard ratio, 0.60). Longer median overall survival was also seen with lenvatinib plus pembrolizumab versus chemotherapy (overall: 18.3 versus 11.4 months; hazard ratio, 0.62; pMMR population: 17.4 versus 12.0 months; hazard ratio for death, 0.68). Overall, 88.9 and 72.7 percent of patients who received lenvatinib plus pembrolizumab and chemotherapy, respectively, had adverse events of grade 3 or higher.<\/p>\n “These benefits in progression-free survival and overall survival were seen across all evaluated subgroups, including subgroups defined according to less-common yet aggressive histologic features, history of pelvic irradiation, and previous lines of therapy,” the authors write.<\/p>\n The study was funded by the manufacturers of lenvatinib (Eisai) and pembrolizumab (Merck Sharp & Dohme).<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n